Unicycive Therapeutics, Inc.
UNCY · Pharmaceutical Preparations · 26.7M shares · -17%/yr ↓ buyback · EDGAR filings ↗
Grade
D42Clinical/early-stage biotech — renal clinical, funded.
Strengths
- Liquidity — current ratio 2.6 (35th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Cash burnNegative free cash flow (-31.3M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Exec changeRecent 8-K item 5.02 8-K ↗
- Buying back stockNet buyback — share count -17%/yr over 3y
- AccumulatingInstitutional holders rose 5→6 QoQ (2025-12-31→2026-03-31)
- Notable holderHeld by 4 notable fund(s): CITADEL ADVISORS LLC, STATE STREET CORP, GOLDMAN SACHS GROUP INC +1 more (as of 2026-03-31)
- New fund positionNotable fund(s) opened this quarter: GOLDMAN SACHS GROUP INC, RENAISSANCE TECHNOLOGIES LLC
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-87.9%
Return on assets
-54.0%
Current ratio
2.6×
Free cash flow
-$31M
Tangible book value
$30M
Cash & investments
$41M
Cash runway
5q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-08-25 | Aggarwal Gaurav | Conversion | 653K | — |
| 2025-02-18 | Aggarwal Gaurav | Conversion | 1.4M | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06218290 ↗ | A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis Chronic Kidney Disease Requiring Chronic Dialysis | PHASE2 | Completed | 2024-05-29 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-22 | 2026-06-19 | 0001213900-26-070316 ↗ |
| 8-K | 2026-06-05 | 2026-06-05 | 0001213900-26-065828 ↗ |
| 8-K | 2026-05-12 | 2026-05-12 | 0001213900-26-054736 ↗ |
| 10-Q | 2026-05-12 | 2026-03-31 | 0001213900-26-054708 ↗ |
| 8-K | 2026-04-06 | 2026-04-06 | 0001213900-26-040179 ↗ |
| 10-K | 2026-03-30 | 2025-12-31 | 0001213900-26-035903 ↗ |
| 8-K | 2026-03-30 | 2026-03-30 | 0001213900-26-035961 ↗ |
| 8-K | 2025-11-14 | 2025-11-14 | 0001213900-25-111045 ↗ |
| 10-Q | 2025-11-12 | 2025-09-30 | 0001213900-25-108600 ↗ |
| 8-K | 2025-11-12 | 2025-11-12 | 0001213900-25-108847 ↗ |
| 8-K | 2025-10-28 | 2025-10-28 | 0001213900-25-102790 ↗ |
| 8-K | 2025-08-18 | 2025-08-15 | 0001213900-25-077937 ↗ |